Several direct-acting antivirals (DAAs) have been approved for the treatment of chronic hepatitis C virus (HCV) infections, opening the door to highly effective interferon-free treatment regimens. Resistance-associated substitutions (RASs) have been reported both in treatment-naïve patients and following treatment with protease (NS3), phosphoprotein (NS5A) and polymerase (NS5B) inhibitors. The prevalence of naturally occurring RASs in untreated HCV-infected individuals has mostly been analysed in those infected with genotype 1 (GT1), in the late phase of infection, and only within limited regions of the genome. Furthermore, the geographic distribution of RASs remains poorly characterized. In this study, we used next-generation sequencing to analyse full-length HCV genomes for the prevalence of RASs in acute HCV infections identified in nine international prospective cohorts. RASs were analysed in 179 participants infected with all six major HCV genotypes (GT1-GT6), and the geographic distribution of RASs was assessed in 107 GT1a and GT3a samples. While RASs were detected at varied frequencies across the three genomic regions, and between genotypes, RASs relevant to multiple DAAs in the leading IFN-free regimens were rarely detected in combination. Low-frequency RASs (<10% of the viral population) were also shown to have a GT-specific distribution. The main RASs with geographic associations were NS3 Q80K in GT1a samples and NS5B N142T in GT3a. These data provide the backdrop for prospective surveillance of RASs during DAA treatment scale-up. 
| INTRODUCTION
In recent years, treatment of hepatitis C virus (HCV) has undergone a major transformation with the arrival of direct-acting antivirals In vitro analysis of the effectiveness of these DAAs has revealed that, in many cases, a single amino acid substitution within the target viral protein can cause a significant loss of antiviral potency. As such, resistance-associated substitutions (RASs) could have a substantial impact on treatment cure rates in vivo, particularly in difficult-to-treat genotypes (GT1a and GT3) or patients with cirrhosis [reviewed in 2 ]. In addition, the high diversity of HCV has meant that many viral isolates naturally carry residues which confer resistance to some approved DAAs as well as those in development. 3, 4 Studies analysing the prevalence of HCV RASs in treatment-naïve Finally, the co-occurrence of low-frequency substitutions across NS3, NS5A and NS5B within a single infection remains unclear. The aim of this study was to perform a comprehensive, ultradeep analysis of the prevalence of RASs in samples from individuals acutely infected with HCV. We compared the prevalence of these RASs across all six major genotypes, and the relative distribution of RASs across three continents.
| MATERIALS AND METHODS

| Study population and design
Participants included in this study were selected from nine prospec- 
| RNA extraction, amplicon generation and sequencing
Viral RNA was extracted from plasma samples, and amplicons covering the HCV genome were generated, either as single near-full-length products, or as three overlapping fragments, as described previously. 12, 13 Due to primer-design limitations, GT4a, GT4d and GT5a amplicons only extended to genome position 9277 (with reference to GT1a strain H77), and NS5B RASs past this position were not analysed. Amplicons were sequenced using either the Roche 454 FLX (n=9) or an Illumina MiSeq benchtop (n=170) sequencing platform as described previously.
12,13
| Sequence alignment and SNP detection
Sequence alignments were generated using Bowtie 2 14 against the corresponding genotype reference sequence (GenBank accession numbers shown in brackets): GT1a (AF009606), GT1b (AJ238799),
GT6a (Y12083), GT6I (EF424628). Single nucleotide polymorphism (SNP) analysis was performed using the Geneious software package version 8 15 with minimum variant frequency threshold of 0.001, maximum variant P-value of 10 −6 and a minimum coverage of 1000.
| RESULTS
| Study population
In total, sequence data were generated for samples collected from 179 cohort participants during acute HCV infection between 2000 and 2014. The mean age of these participants was 26.5 (standard deviation 8.1 years), 69% were male, and 5.6% were co-infected with HIV. All participants were naïve to HCV treatment. The majority of participants were infected with HCV GT1a (41.3%, n=74) and GT3a
(36.3%, n=65). A minority of participants were infected with HCV GT1b (n=5), GT2a (n=2), GT2b (n=12), GT4a (n=7), GT4d (n=5), 4m
(n=1), GT5a (n=4), GT6a (n=3) and GT6i (n=1). The distribution of HCV genotypes stratified by country of origin is shown in Table 1 . 
| Resistance substitution prevalence
The prevalence of the analysed RASs in the entire data set is summarized in Figure 1 . It is worth noting that the prevalence of RASs in the study population varied depending on the frequency threshold set within the viral quasispecies. To allow comparisons between our data set and other studies, the prevalence of each RAS was assessed with a range of frequency thresholds ( Figures S1-S3 ). The prevalence of RASs in the data set increased when low-frequency thresholds were considered (i.e. <2%) for most genome positions. However, the calculated prevalence of RASs did not vary greatly when this threshold was raised above the level of 10% (Figures S1-S3 ). Hence, 10% was the threshold assigned to designate either "high-frequency" or "lowfrequency" substitutions. While this study examined all reported RASs 
| Resistance substitutions within the NS3 coding region
Within NS3, substitutions at position 36 were only observed at frequencies below 2% in GT1 and GT6 sequences, and the consensuslevel substitution L36 was observed in GT2-GT5 sequences (Table   S1 ). The RAS Q80K was detected at frequencies >10% in 22 of 74
GT1a samples (30% , Table S1 ), and as the consensus residue for all GT5a and GT6a ( Figure 1 ). The substitution, S122R, was only detected in GT2b subtypes ( Figure 1 ). RASs at NS3 S43, T54, V55, R155
and V170 were only detected in a minority of sequences at high frequencies (>10%) ( Figure S1 ), while 2 of 5 GT1b sequences carried consensus-level V132. NS3 RASs at Y56 were more common at low frequency in GT1a samples and absent from all GT5a samples.
The large majority (84%) of samples included in the study, with the exception of GT4a samples, carried the low-frequency substitutions A156T/V. NS3 Q168 was the dominant residue in all but one GT3a sequence, which instead carried H168 (Table S1 ).
To analyse the geographic distribution of NS3 RASs, GT1a and GT3a samples obtained from North America and Australia were compared. The only NS3 RAS with a significant geographic difference was Q80K (P<.001, Table S2 ). The prevalence of Q80K was lower among participants with GT1a from Australia (1 of 25, 4%) compared to participants with GT1a from North America (20 of 48, 42%).
| Resistance substitutions within the NS5A coding region
Within NS5A, the variant V28 was detected at the consensus level in 2 of 74 (3%) GT1a samples, in the GT6i sample. This RAS was also detected at high frequencies (18-49%) in 1 of 74 GT1a and 1 of 65 GT3a samples, respectively ( Figure 1 and Table S1 ). Low-frequency RASs at this position could not be detected in any of the GT1b and GT5a samples, but were present at differing levels in all other GTs. In GT1a participants, 2 of 48 (4%) samples derived from North America, but none of the Australian-derived sequences, carried the variant H30 (Table   S1 ). A30K/T was detected in 3 of 65 GT3a sequences (Figure 1) . RAS L31F could be detected at low frequencies in GT3a samples, while L31M was detected at high frequency in 6 of 12 GT2b samples. GT2
and GT4a samples, in addition to consensus-level M31 variants, carried low-frequency (<2%) L31V/I (Figure 1 ). NS5A 32 and 38 substitutions were only detected at very low frequencies across genotypes.
The RAS Y93S was only detected in 1 of 74 GT1a sequences, while Y93H was detected in 1 of 65 GT3a samples. Another GT3a and a GT4a sample carried this RAS at high frequencies (39% and 57%, respectively). One of 74 GT1a participants carried R24 at 44%, and one GT3a participant carried E26 at 26% frequency ( Figure 1) . No significant geographic differences were observed for NS5A RASs in our data set with either GT1a or GT3a.
| Resistance substitutions within the NS5B coding region
RASs associated with the nucleoside inhibitor (NI) sofosbuvir (positions 159, 282, 289, 320 and 321) were rarely detected in our data set. L159F was detected in one GT1a sample, which carried this RAS as the dominant variant, while substitutions at M289 were detected as majority variants in two GT2b samples (Figure 1 ). Low-frequency substitutions were detected at position 321 and were primarily alanine residues for all genotypes.
Resistance to the recently approved non-nucleoside inhibitor and S556G (4 of 74) were detected at frequencies >10%, and only S556G substitutions were detected at the consensus level ( Figure 1 and Figure S3 ). Low-frequency RAS C316Y was also detected across all GTs (Figure 1 ). Of the GT1b samples, one of five (20%) carried the S556G substitution at a frequency of 42%. Lower-frequency substitutions associated with dasabuvir were present in all GT1 samples, while GT4 samples carried subtype-specific substitutions M414V/I/L. RASs V553 and G556 were also present at the consensus level in different subtypes (Table S1 ).
Of the NS5B substitutions associated with resistance to beclabuvir, A421V was present at a frequency >10% both in Australianderived (24%) and North American-derived (10%) GT1a samples, and almost all GT1a samples carried this RAS at lower frequencies (0.2-4%). RASs at position 495 were only detected at frequencies up to 4.8% (Figure 1 ). Substitutions associated with a class of NNIs binding to the thumb II site, including L419I, M423I, I482L and V494A, were genotype and subtype specific (Figure 1) , and with the exception of GT1b samples, >97% of all non-GT1b samples had consensus-level NS5B V499A (Table S1 ).
The NS5B RASs N142T was only detected in GT3a samples de- 
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| DISCUSSION
The rapid evolution of HCV therapeutics has generated a need for a better understanding of the mutations encoding for resistance against antiviral agents in the clinical setting. The aim of this study was to understand the prevalence of RASs during the acute phase of HCV infection, and how they differed across genotypes and between geographic regions.
The large number of samples representing the major GTs in this study allowed the direct comparison of RAS prevalence between GTs, particularly between GT1a and GT3a (Table S1 ). Notable differences detected in this analysis included NS3 Q80K, which was associated with GT1a samples, and NS5B N142T, which was associated with GT3a. Understanding these genotypic differences is crucial for future therapies where pan-genotypic regimens are the ultimate goal. Our analysis has also demonstrated differences in the prevalence of some RASs within the same genotype, but across different geographic regions. The geographical association of the NS5B RAS, N142T, has not been previously reported, which may be due to the lack of large-scale analyses of GT3a-associated RASs. This substitution has been associated with resistance to some HCV NIs, 18, 19 but had no effect on the potency of sofosbuvir in vitro 20 or treatment outcome in vivo. 18 The geographic spread of NS3 Q80K has been well documented, reaching levels of 48% in North American GT1a isolates, between 0% and 19%
in Europe and 9% in South America. 21, 22 In this study, and in agreement with previous reports, the prevalence of this RAS in GT1a samples from the North American continent was 38%. However, only 4%
of GT1a sequences of Australian origin carried this substitution. This RAS has been associated with resistance to a number of approved NS3
inhibitors including simeprevir and paritaprevir.
Despite the uncertainty regarding the clinically relevant thresholds for RAS detection, it is worth noting that the prevalence of lowfrequency (<10%) RASs varied across different genome positions, and across HCV genotypes. NS3 RASs A156T/V, for instance, were detected at low frequencies in the majority of samples, with the exception of those belonging to GT4a HCV. This is despite the apparent fitness cost these substitutions confer to GT1a/1b in vitro. 23 Similarly, NS5A RASs M28T/V were detected at low frequencies in a large number of samples ( Figure 1 ). Other substitutions which had a GT-specific prevalence included NS3 Q80, which could not be detected in GT2b, while S122R was rarely detected in non-GT2b samples. Similarly, a notable absence of the following RASs was observed in specific genotypes: NS3 Y56H/I in GT5a, NS3 R155 RASs in GT4a, NS5A L31I/V in GT1a/1b, 5a and 6a and NS5B M414T/I/L/V in GT2 samples ( Figure 1 ). It is known that the genetic barrier to resistance not only differs between classes of DAAs, 3, 24 but also between different HCV subtypes towards the same DAA.
3 This is believed to be attributable to the number and type of nucleotide changes required to generate these RASs, and the fitness cost of these RASs in different genotypes. 25 Better understanding of these genotypic differences in tolerance to even low-frequency variations that are associated with DAA resistance may provide a valuable insight into which molecules could be targeted for pan-genotypic regimens, and which genotypes might need screening for antiviral resistance before or during therapy.
In summary, this is the largest study assessing the prevalence of HCV-related resistance substitutions in acute infection to characterize whether these RASs are commonly associated with transmitted substitutions. It provides the most comprehensive estimate of the prevalence of HCV RASs across the HCV genome for six different genotypes across three continents using deep sequencing, which is needed if these emerging therapies are to be applied on a global scale.
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